Allosteric GABAA Receptor Modulators-A Review on the Most Recent Heterocyclic Chemotypes and Their Synthetic Accessibility

被引：20

作者：

Alanis, Blanca Angelica Vega ^{[1
]}

Iorio, Maria Teresa ^{[1
]}

Silva, Luca L. ^{[2
]}

Bampali, Konstantina ^{[3
]}

Ernst, Margot ^{[3
]}

Schnuerch, Michael ^{[1
]}

Mihovilovic, Marko D. ^{[1
]}

机构：

[1] TU Wien, Inst Appl Synthet Chem, Getreidemarkt 9-193, A-1060 Vienna, Austria

[2] Charite, Dept Anesthesiol & Intens Care Med, Charitepl 1, D-10117 Berlin, Germany

[3] Med Univ Vienna, Ctr Brain Res, Dept Mol Neurosci, Spitalgasse 4, A-1090 Vienna, Austria

来源：

MOLECULES | 2020年 / 25卷 / 04期

基金：

奥地利科学基金会;

关键词：

GABA(A) modulators; allosteric modulators; heterocyclic modulators; heterocyclic synthesis; nitrogen heterocycles; GAMMA-AMINOBUTYRIC-ACID; HIGH-AFFINITY; IN-VITRO; BENZODIAZEPINE SITE; PHARMACOKINETIC PROPERTIES; ANTICONVULSANT ACTIVITY; INTERNATIONAL UNION; BIOLOGICAL-ACTIVITY; EFFICIENT SYNTHESIS; SELECTIVE LIGANDS;

D O I：

10.3390/molecules25040999

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

GABA(A) receptor modulators are structurally almost as diverse as their target protein. A plethora of heterocyclic scaffolds has been described as modulating this extremely important receptor family. Some made it into clinical trials and, even on the market, some were dismissed. This review focuses on the synthetic accessibility and potential for library synthesis of GABA(A) receptor modulators containing at least one heterocyclic scaffold, which were disclosed within the last 10 years.

引用

页数：47

共 163 条

[91] A pharmacological characterization of GABA, THIP and DS2 at binary α4β3 and β3δ receptors: GABA activates β3δ receptors via the β3(+)δ (-) interface
Lee, H. J.
Absalom, N. L.
Hanrahan, J. R.
van Nieuwenhuijzen, P.
Ahring, P. K.
Chebib, M.
[J]. BRAIN RESEARCH, 2016, 1644 : 222 - 230
[92] Lemon MD, 2009, DRUG DES DEV THER, V3, P131
[93] Improved Synthesis of Anxiolytic, Anticonvulsant, and Antinociceptive α2/α3-GABA(A)-ergic Receptor Subtype Selective Ligands as Promising Agents to Treat Anxiety, Epilepsy, and Neuropathic
Li, Guanguan
Golani, Lalit K.
Jahan, Rajwana
Rashid, Farjana
Cook, James M.
[J]. SYNTHESIS-STUTTGART, 2018, 50 (20): : 4124 - 4132
[94] Eszopiclone for the treatment of primary insomnia: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials
Liang, Liang
Huang, Yabing
Xu, Rong
Wei, Yanyan
Xiao, Ling
Wang, Gaohua
[J]. SLEEP MEDICINE, 2019, 62 : 6 - 13
[95] Liu J.F., 2011, WO, Patent No. 2011047315
[96] How theories evolved concerning the mechanism of action of barbiturates
Loescher, Wolfgang
Rogawski, Michael A.
[J]. EPILEPSIA, 2012, 53 : 12 - 25
[97] Synthesis and pharmacological evaluation of pyrazolo [4,3-c]quinolinones as high affinity GABAA-R ligands and potential anxiolytics
Lopez Rivilli, Marisa J.
Turina, Anahi V.
Bignante, Elena A.
Molina, Victor H.
Perillo, Maria A.
Brinon, Margarita C.
Moyano, Elizabeth L.
[J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2018, 26 (14) : 3967 - 3974
[98] One-Pot Synthesis of Triazolobenzodiazepines Through Decarboxylative [3+2] Cycloaddition of Nonstabilized Azomethine Ylides and Cu-Free Click Reactions
Ma, Xiaoming
Zhang, Xiaofeng
Qiu, Weiqi
Zhang, Wensheng
Wan, Bruce
Evans, Jason
Zhang, Wei
[J]. MOLECULES, 2019, 24 (03)
[99] Mainfeld A., 2008, US, Patent No. 20080015197
[100] Malapero Raymond J, 2017, J Anaesthesiol Clin Pharmacol, V33, P429, DOI 10.4103/0970-9185.222521

← 5 6 7 8 9 10 11 12 13 14 →